Wolverine Trading’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.55M | Buy |
+24,200
| New | +$1.18M | ﹤0.01% | 2437 |
|
|
2025
Q2 | – | Sell |
-14,500
| Closed | -$452K | – | 5157 |
|
|
2025
Q1 | $452K | Buy |
14,500
+6,900
| +91% | +$226K | ﹤0.01% | 3086 |
|
|
2024
Q4 | $265K | Sell |
7,600
-10,900
| -59% | -$407K | ﹤0.01% | 4166 |
|
|
2024
Q3 | $756K | Sell |
18,500
-3,200
| -15% | -$149K | ﹤0.01% | 2645 |
|
|
2024
Q2 | $1.03M | Buy |
21,700
+12,200
| +128% | +$500K | ﹤0.01% | 2164 |
|
|
2024
Q1 | $412K | Buy |
9,500
+2,300
| +32% | +$110K | ﹤0.01% | 3040 |
|
|
2023
Q4 | $364K | Sell |
7,200
-3,500
| -33% | -$168K | ﹤0.01% | 3279 |
|
|
2023
Q3 | $485K | Buy |
+10,700
| New | +$441K | ﹤0.01% | 2804 |
|
|
2023
Q1 | – | Sell |
-10,000
| Closed | -$378K | – | 4569 |
|
|
2022
Q4 | $378K | Buy |
+10,000
| New | +$421K | ﹤0.01% | 2576 |
|
|
2022
Q2 | – | Sell |
-11,400
| Closed | -$407K | – | 5088 |
|
|
2022
Q1 | $407K | Buy |
11,400
+1,000
| +10% | +$32.7K | ﹤0.01% | 3503 |
|
|
2021
Q4 | $318K | Buy |
+10,400
| New | +$327K | ﹤0.01% | 4066 |
|
|
2021
Q3 | – | Sell |
-26,700
| Closed | -$1.06M | – | 6572 |
|
|
2021
Q2 | $1.06M | Buy |
26,700
+3,100
| +13% | +$121K | ﹤0.01% | 2716 |
|
|
2021
Q1 | $1.05M | Sell |
23,600
-27,700
| -54% | -$1.54M | ﹤0.01% | 2687 |
|
|
2020
Q4 | $2.93M | Buy |
51,300
+39,300
| +328% | +$1.96M | ﹤0.01% | 1420 |
|
|
2020
Q3 | $582K | Sell |
12,000
-4,600
| -28% | -$256K | ﹤0.01% | 2649 |
|
|
2020
Q2 | $986K | Sell |
16,600
-6,700
| -29% | -$373K | ﹤0.01% | 2015 |
|
|
2020
Q1 | $1.12M | Sell |
23,300
-43,700
| -65% | -$2.44M | ﹤0.01% | 1811 |
|
|
2019
Q4 | $4.04M | Buy |
67,000
+2,200
| +3% | +$131K | 0.01% | 1263 |
|
|
2019
Q3 | $3.83M | Buy |
64,800
+2,700
| +4% | +$176K | 0.01% | 1018 |
|
|
2019
Q2 | $3.99M | Sell |
62,100
-11,300
| -15% | -$799K | 0.01% | 1040 |
|
|
2019
Q1 | $5.96M | Buy |
73,400
+46,300
| +171% | +$2.99M | 0.02% | 783 |
|
|
2018
Q4 | $1.39M | Sell |
27,100
-42,500
| -61% | -$2.17M | ﹤0.01% | 1712 |
|
|
2018
Q3 | $3.59M | Sell |
69,600
-3,400
| -5% | -$160K | 0.01% | 1201 |
|
|
2018
Q2 | $3.22M | Hold |
73,000
| – | – | 0.01% | 1208 |
|
|
2018
Q1 | $3.22M | Buy |
73,000
+9,200
| +14% | +$467K | 0.01% | 1208 |
|
|
2017
Q4 | $3.21M | Sell |
63,800
-100
| -0.2% | -$5.48K | 0.01% | 1163 |
|
|
2017
Q3 | $3.24M | Buy |
63,900
+13,600
| +27% | +$712K | 0.01% | 1029 |
|
|
2017
Q2 | $2.61M | Sell |
50,300
-5,000
| -9% | -$233K | 0.01% | 1064 |
|
|
2017
Q1 | $2.23M | Sell |
55,300
-60,800
| -52% | -$2.73M | 0.01% | 1113 |
|
|
2016
Q4 | $5.55M | Sell |
116,100
-11,200
| -9% | -$443K | 0.03% | 669 |
|
|
2016
Q3 | $4.53M | Buy |
127,300
+23,900
| +23% | +$748K | 0.02% | 792 |
|
|
2016
Q2 | $2.39M | Buy |
+103,400
| New | +$3.34M | 0.01% | 995 |
|
Other funds holding IONS
BG
DTC
Wolverine Trading's IONS Position: Q3 2025 in Review
Wolverine Trading opened a new position in Ionis Pharmaceuticals (IONS) in Q3 2025: 27,585 shares worth $1.77M. The stake represents ﹤0.01% of the portfolio and ranks #2297 among its holdings. This is a return to the name: Wolverine Trading previously reported a position in IONS as recently as Q4 2024.
Wolverine Trading first reported a position in IONS in Q2 2016 and has held it in 29 quarters since. The position peaked at $9.72M in Q3 2020. 435 funds tracked by Wall St. Rank hold IONS as of Q3 2025.
- Wolverine Trading held 27,585 shares of Ionis Pharmaceuticals worth $1.77M as of Q3 2025.
- Ionis Pharmaceuticals was a new Wolverine Trading position in Q3 2025.
- Ionis Pharmaceuticals made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #2297 holding.
- Wolverine Trading first reported a position in Ionis Pharmaceuticals in Q2 2016 and has held it in 29 quarters since.
- Wolverine Trading's Ionis Pharmaceuticals position peaked at $9.72M in Q3 2020.
- 435 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.